Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CENOBAMATE

All strengths: Limited Use — Reason for Use code 719 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 719 required
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N03AX) — coverage varies; not interchangeable

  • Lamotrigine (Lamictal): general benefit
  • Topiramate (Topamax Sprinkle): general benefit, Limited Use 321, Not a benefit
  • Brivaracetam (Brivlera): limited Use 548
  • Lacosamide (Vimpat): limited Use 430
  • Levetiracetam (PDP-Levetiracetam): limited Use 473, Limited Use 640, 705
  • Perampanel (Fycompa): limited Use 430, 564

14 more in the class list below

Xcopri · DIN 02538652 · 12.5mg · tablet

Limited Use — Reason for Use code 719 requiredMarketed · checked 2026-09-02
Write on scriptLU code 719 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 719
Reason for Use code 719 As adjunctive therapy in the treatment of patients with partial onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Xcopri · DIN 02538652 Manufacturer: Knight Therapeutics Inc.; listing date 2025-05-30 Health Canada: Marketed since 2025-12-19 · brand XCOPRI · ATC N03AX25 CENOBAMATE · form Tablet · route Oral · ingredients CENOBAMATE 12.5 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Xcopri: Formulary list price $8.9580/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.9580 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102735 · Verify on the e-Formulary ↗ (DIN 02538652)

Source record
DIN 02538652: Xcopri Raw flags: sec12=Y, sec3=Y Item: 281200189; group id 424; item number 1049; lccId 00409; manufacturer id KNT Source form: Tab; strength: 12.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $8.9580; ministry $8.9580 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538652 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102735
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538652
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Xcopri · DIN 02538776 · 12.5mg & 25mg · tablet - (Starter Kit)

Limited Use — Reason for Use code 719 requiredMarketed · checked 2026-09-02
Write on scriptLU code 719 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 719
Reason for Use code 719 As adjunctive therapy in the treatment of patients with partial onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Xcopri · DIN 02538776 Manufacturer: Knight Therapeutics Inc.; listing date 2025-05-30 Health Canada: Marketed since 2025-12-19 · brand XCOPRI · ATC N03AX25 CENOBAMATE · form Kit, Tablet · route Oral · ingredients CENOBAMATE 25 MG, CENOBAMATE 12.5 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Xcopri: Formulary list price $8.9580/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.9580 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102746 · Verify on the e-Formulary ↗ (DIN 02538776)

Source record
DIN 02538776: Xcopri Raw flags: sec12=Y, sec3=Y Item: 281200195; group id 424; item number 1055; lccId 00409; manufacturer id KNT Source form: Tab - (Starter Kit); strength: 12.5mg & 25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $8.9580; ministry $8.9580 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538776 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102746
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538776
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Xcopri · DIN 02538660 · 25mg · tablet

Limited Use — Reason for Use code 719 requiredMarketed · checked 2026-09-02
Write on scriptLU code 719 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 719
Reason for Use code 719 As adjunctive therapy in the treatment of patients with partial onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Xcopri · DIN 02538660 Manufacturer: Knight Therapeutics Inc.; listing date 2025-05-30 Health Canada: Marketed since 2025-12-19 · brand XCOPRI · ATC N03AX25 CENOBAMATE · form Tablet · route Oral · ingredients CENOBAMATE 25 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Xcopri: Formulary list price $8.9580/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.9580 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102736 · Verify on the e-Formulary ↗ (DIN 02538660)

Source record
DIN 02538660: Xcopri Raw flags: sec12=Y, sec3=Y Item: 281200190; group id 424; item number 1050; lccId 00409; manufacturer id KNT Source form: Tab; strength: 25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $8.9580; ministry $8.9580 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538660 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102736
Shortage status: resolved shortage (ended 2025-12-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538660
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Xcopri · DIN 02538725 · 50mg · tablet

Limited Use — Reason for Use code 719 requiredMarketed · checked 2026-09-02
Write on scriptLU code 719 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 719
Reason for Use code 719 As adjunctive therapy in the treatment of patients with partial onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Xcopri · DIN 02538725 Manufacturer: Knight Therapeutics Inc.; listing date 2025-05-30 Health Canada: Marketed since 2025-12-19 · brand XCOPRI · ATC N03AX25 CENOBAMATE · form Tablet · route Oral · ingredients CENOBAMATE 50 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Xcopri: Formulary list price $8.9580/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.9580 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102738 · Verify on the e-Formulary ↗ (DIN 02538725)

Source record
DIN 02538725: Xcopri Raw flags: sec12=Y, sec3=Y Item: 281200191; group id 424; item number 1051; lccId 00409; manufacturer id KNT Source form: Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $8.9580; ministry $8.9580 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538725 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102738
Shortage status: resolved shortage (ended 2026-04-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538725
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Xcopri · DIN 02538784 · 50mg & 100mg · tablet - (Starter Kit)

Limited Use — Reason for Use code 719 requiredMarketed · checked 2026-09-02
Write on scriptLU code 719 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 719
Reason for Use code 719 As adjunctive therapy in the treatment of patients with partial onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Xcopri · DIN 02538784 Manufacturer: Knight Therapeutics Inc.; listing date 2025-05-30 Health Canada: Marketed since 2025-12-19 · brand XCOPRI · ATC N03AX25 CENOBAMATE · form Kit, Tablet · route Oral · ingredients CENOBAMATE 100 MG, CENOBAMATE 50 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Xcopri: Formulary list price $8.9580/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.9580 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102747 · Verify on the e-Formulary ↗ (DIN 02538784)

Source record
DIN 02538784: Xcopri Raw flags: sec12=Y, sec3=Y Item: 281200196; group id 424; item number 1056; lccId 00409; manufacturer id KNT Source form: Tab - (Starter Kit); strength: 50mg & 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $8.9580; ministry $8.9580 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538784 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102747
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538784
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Xcopri · DIN 02538733 · 100mg · tablet

Limited Use — Reason for Use code 719 requiredMarketed · checked 2026-09-02
Write on scriptLU code 719 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 719
Reason for Use code 719 As adjunctive therapy in the treatment of patients with partial onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Xcopri · DIN 02538733 Manufacturer: Knight Therapeutics Inc.; listing date 2025-05-30 Health Canada: Marketed since 2025-12-19 · brand XCOPRI · ATC N03AX25 CENOBAMATE · form Tablet · route Oral · ingredients CENOBAMATE 100 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Xcopri: Formulary list price $8.9580/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.9580 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102743 · Verify on the e-Formulary ↗ (DIN 02538733)

Source record
DIN 02538733: Xcopri Raw flags: sec12=Y, sec3=Y Item: 281200192; group id 424; item number 1052; lccId 00409; manufacturer id KNT Source form: Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $8.9580; ministry $8.9580 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538733 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102743
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538733
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Xcopri · DIN 02538741 · 150mg · tablet

Limited Use — Reason for Use code 719 requiredMarketed · checked 2026-09-02
Write on scriptLU code 719 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 719
Reason for Use code 719 As adjunctive therapy in the treatment of patients with partial onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Xcopri · DIN 02538741 Manufacturer: Knight Therapeutics Inc.; listing date 2025-05-30 Health Canada: Marketed since 2025-12-19 · brand XCOPRI · ATC N03AX25 CENOBAMATE · form Tablet · route Oral · ingredients CENOBAMATE 150 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Xcopri: Formulary list price $8.9580/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.9580 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102744 · Verify on the e-Formulary ↗ (DIN 02538741)

Source record
DIN 02538741: Xcopri Raw flags: sec12=Y, sec3=Y Item: 281200193; group id 424; item number 1053; lccId 00409; manufacturer id KNT Source form: Tab; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $8.9580; ministry $8.9580 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538741 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102744
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538741
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Xcopri · DIN 02538768 · 200mg · tablet

Limited Use — Reason for Use code 719 requiredMarketed · checked 2026-09-02
Write on scriptLU code 719 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 719
Reason for Use code 719 As adjunctive therapy in the treatment of patients with partial onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Xcopri · DIN 02538768 Manufacturer: Knight Therapeutics Inc.; listing date 2025-05-30 Health Canada: Marketed since 2025-12-19 · brand XCOPRI · ATC N03AX25 CENOBAMATE · form Tablet · route Oral · ingredients CENOBAMATE 200 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Xcopri: Formulary list price $8.9580/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.9580 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102745 · Verify on the e-Formulary ↗ (DIN 02538768)

Source record
DIN 02538768: Xcopri Raw flags: sec12=Y, sec3=Y Item: 281200194; group id 424; item number 1054; lccId 00409; manufacturer id KNT Source form: Tab; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $8.9580; ministry $8.9580 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538768 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102745
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538768
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Xcopri · DIN 02538792 · 150mg & 200mg · tablet - (Starter Kit)

Limited Use — Reason for Use code 719 requiredApproved · checked 2026-09-02
Write on scriptLU code 719 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 719
Reason for Use code 719 As adjunctive therapy in the treatment of patients with partial onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Xcopri · DIN 02538792 Manufacturer: Knight Therapeutics Inc.; listing date 2025-05-30 Health Canada: Approved since 2025-12-19 · brand XCOPRI · ATC N03AX25 CENOBAMATE · form Kit, Tablet · route Oral · ingredients CENOBAMATE 150 MG, CENOBAMATE 200 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Xcopri: Formulary list price $8.8000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.8000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102748 · Verify on the e-Formulary ↗ (DIN 02538792)

Source record
DIN 02538792: Xcopri Raw flags: sec12=Y, sec3=Y Item: 281200197; group id 424; item number 1057; lccId 00409; manufacturer id KNT Source form: Tab - (Starter Kit); strength: 150mg & 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $8.8000; ministry $8.8000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538792 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102748
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538792
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Approved since 2025-12-19 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab

LACOSAMIDE

· 44 products · Limited Use, codes 430 · strengths: 50mg, 100mg, 150mg, 200mg · Tab

LEVETIRACETAM

· 49 products · Limited Use, codes 640, 705 (3), Limited Use, codes 473 (46) · strengths: 100mg/mL, 250mg, 500mg, 750mg, 1000mg · Oral Sol, Tab

PERAMPANEL

· 12 products · Limited Use, codes 430, 564 · strengths: 2mg, 4mg, 6mg, 8mg, 10mg, 12mg · Tab

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS XCOPRI (cenobamate tablets) is indicated as: • adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥65 years of age): Clinical studies of XCOPRI did not include enough patients aged 65 years and over (n = 48) to determine whether they respond differently compared to younger patients. In general, dose selection for an elderly patient should start at the low end of the dosing range and be maintained at the lowest effective dose, reflecting the greater frequency in this subpopulation of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See 7.1 Special Populations and 10.3 Pharmacokinetics, Special Populations and Conditions, Geriatrics). https://pdf.hres.ca/dpd_pm/00082935.PDF PM date: JUN 12, 2023 Source product: XCOPRI; DIN 02538652; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.